| Financier | Commitments |
|---|---|
| IDA Grant | 100.00 |
| IDA Grant | 100.00 |
Support to COVID-19 Vaccine Purchase and Health System Strengthening
Abstract*
The Project Development Objective (PDO) is to support the GoM to acquire and deploy COVID-19 vaccines and strengthen its immunization services. The parent project includes the components as listed below.
The parent project includes the components as listed below. Component 1: Acquisition of Vaccines and Medical Supplies. This component supports vaccine acquisition. The acquisition is expected to be implemented through the Africa Union Vaccine Acquisition... Show More
Development Objective
This Project’s Development Objective is to support the Government of Madagascar to acquire and deploy COVID-19 vaccines, and to strengthen its immunization services.
Key Details
Project Details
P176841
Active
Cedric Ndizeye
Government of Madagascar,Government of Madagascar
June 2, 2021
(as of board presentation)
June 24, 2021
July 26, 2021
US$ 100.00 million
Ministry of Public Health,Ministry of Public Health
2021
US$ 100.00 million
N/A
Substantial
June 30, 2025
Yes
BANK APPROVED
May 21, 2024
Finances
Financing Plan (US$ Millions)
Total Project Financing (US$ Millions)
| Product Line | IBRD/IDA |
|---|---|
| IBRD Commitment | N/A |
| IDA Commitment | 100.00 |
| IBRD + IDA Commitment | 100.00 |
| Lending Instrument | |
|---|---|
| Grant Amount | N/A |
| Total Project Cost** | 100.00 |
Summary Status of World Bank Financing (US$ Millions) as of March 31, 2025
No data available.
| Period | Financier | Transaction Type | Amount (US$) |
|---|---|---|---|
| Feb 13, 2024 | IDA-D8930 | Loan Disb | 864,655.70 |
| Jun 3, 2024 | IDA-D8930 | Loan Disb | 1,124,066.60 |
| Jun 26, 2024 | IDA-D8930 | Loan Disb | -2,867,179.20 |
| Dec 22, 2021 | IDA-D9630 | Loan Commitment | 41,000,000.00 |
| Jun 21, 2024 | IDA-D8930 | Loan Disb | 9,557,428.00 |
| Jun 20, 2024 | IDA-D8930 | Loan Disb | 2,343,982.00 |
| Jun 24, 2021 | IDA-D8930 | Loan Commitment | 100,000,000.00 |
| Jan 21, 2022 | IDA-D8930 | Loan Disb | 4,349,037.00 |
| Dec 29, 2021 | IDA-D8930 | Loan Disb | 2,237,430.50 |
| Feb 10, 2022 | IDA-D8930 | Loan Disb | 411,317.38 |
| Feb 10, 2022 | IDA-D8930 | Loan Disb | 2,204,496.00 |
| Feb 10, 2022 | IDA-D8930 | Loan Disb | 6,000,000.00 |
| Apr 4, 2022 | IDA-D8930 | Loan Disb | 933,603.60 |
| Dec 16, 2021 | IDA-D8930 | Loan Disb | 6,000,000.00 |
| May 27, 2022 | IDA-D8930 | Loan Disb | 17,454,528.00 |
| Jul 22, 2022 | IDA-D8930 | Loan Disb | 706,657.20 |
| Dec 2, 2021 | IDA-D8930 | Loan Disb | 3,669,567.20 |
| Dec 2, 2021 | IDA-D8930 | Loan Disb | 1,747,267.20 |
| Apr 20, 2022 | IDA-D8930 | Loan Disb | 5,685,606.50 |
| Sep 14, 2022 | IDA-D8930 | Loan Disb | 689,062.94 |
| Nov 14, 2022 | IDA-D8930 | Loan Disb | 784,947.75 |
| Nov 15, 2022 | IDA-D8930 | Loan Disb | 2,394,760.00 |
| Apr 7, 2023 | IDA-D9630 | Loan Cancel | 33,029,430.00 |
| Jun 2, 2023 | IDA-D8930 | Loan Disb | 200,001.00 |
| Sep 19, 2023 | IDA-D8930 | Loan Disb | 112,188.59 |
| May 31, 2023 | IDA-D9630 | Loan Disb | 944,100.00 |
| May 31, 2023 | IDA-D9630 | Loan Disb | 604,899.75 |
| Jul 25, 2023 | IDA-D9630 | Loan Disb | 704,710.44 |
| Dec 26, 2023 | IDA-D8930 | Loan Disb | 3,302,411.00 |
| Jun 30, 2023 | IDA-D9630 | Loan Disb | 636,538.44 |
| Jun 16, 2023 | IDA-D9630 | Loan Disb | 1,572,173.10 |
| Jun 5, 2023 | IDA-D9630 | Loan Disb | 605,057.25 |
| Jun 8, 2023 | IDA-D8930 | Loan Disb | 1,607,893.10 |
| Dec 27, 2023 | IDA-D9630 | Loan Disb | 734,124.44 |
| Jun 26, 2024 | IDA-D8930 | Loan Disb | 4,156,106.00 |
| Feb 27, 2024 | IDA-D8930 | Loan Disb | 2,878,999.50 |
Ratings
IMPLEMENTATION RATINGS
| Name | Review | Date |
|---|---|---|
| Financial Management | Moderately Unsatisfactory | 2024-11-19 |
| Monitoring and Evaluation | Satisfactory | 2024-11-19 |
| Progress towards achievement of PDO | Moderately Satisfactory | 2024-11-19 |
| Procurement | Moderately Satisfactory | 2024-11-19 |
| Project Management | Moderately Satisfactory | 2024-11-19 |
| Overall Implementation Progress (IP) | Moderately Satisfactory | 2024-11-19 |
| Financial Management | Moderately Unsatisfactory | 2024-11-19 |
| Monitoring and Evaluation | Satisfactory | 2024-11-19 |
| Progress towards achievement of PDO | Moderately Satisfactory | 2024-11-19 |
| Procurement | Moderately Satisfactory | 2024-11-19 |
| Project Management | Moderately Satisfactory | 2024-11-19 |
| Overall Implementation Progress (IP) | Moderately Satisfactory | 2024-11-19 |
COMPLETION RATINGS
No data available.
INDEPENDENT EVALUATION RATINGS
No data available.
Results Framework
PROJECT DEVELOPMENT OBJECTIVE INDICATORS
| INDICATOR | BASELINE | CURRENT | TARGET |
|---|
Percentage of the population fully vaccinated, based on prioritized populations as defined in national plan Value 0.00 8.90 20.00 Date April 30, 2021 September 30, 2023 December 31, 2024 Comment Percentage of females fully vaccinated, based on the prioritized population in the national plan Value 0.00 50.26 50.00 Date May 28, 2021 September 30, 2023 June 30, 2024 Comment Percentage of the population fully vaccinated, based on prioritized populations as defined in national plan Value 0.00 8.90 20.00 Date April 30, 2021 September 30, 2023 December 31, 2024 Comment Percentage of females fully vaccinated, based on the prioritized population in the national plan Value 0.00 50.26 50.00 Date May 28, 2021 September 30, 2023 June 30, 2024 Comment
INTERMEDIATE RESULTS INDICATORS
| INDICATOR | BASELINE | CURRENT | TARGET |
|---|
Number of complete doses of eligible COVID-19 vaccine purchased through the project that arrived in the country Value 0.00 2721600.00 2721600.00 Date April 30, 2021 September 30, 2023 December 31, 2024 Comment Number of sites with functioning refrigerators purchased through the project Value 0.00 523.00 540.00 Date April 30, 2021 September 30, 2023 June 30, 2024 Comment Number of health workers trained in vaccine administration within the project Value 0.00 2913.00 4000.00 Date April 30, 2021 September 30, 2023 June 30, 2024 Comment Number of female health workers trained in vaccine administration within the project Value 0.00 1480.00 2200.00 Date April 30, 2021 September 30, 2023 June 30, 2024 Comment Number of vaccination sites that received waste treatment equipment through the project. Value 0.00 2832.00 2720.00 Date April 30, 2021 September 30, 2023 June 30, 2024 Comment Proportion of serious adverse events following immunization (AEFI) reported and investigated based on national guidelines Value 0.00 100.00 100.00 Date April 30, 2021 September 30, 2023 June 30, 2024 Comment Percentage of frontline health care workers with the knowledge to recognize, medically manage, and refer GBV survivors to appropriate services Value 0.00 7.73 24.00 Date April 30, 2021 September 30, 2023 June 30, 2024 Comment Percentage of immunization sites reporting data on time Value 0.00 100.00 80.00 Date April 30, 2021 September 30, 2023 June 30, 2024 Comment Percentage of recorded grievances that are addressed in a timely manner Value 0.00 78.00 75.00 Date April 30, 2021 September 30, 2023 June 30, 2024 Comment Percentage of doses successfully administered out of the total vaccine doses procured by the Project Value 0.00 5.50 70.00 Date December 1, 2021 September 30, 2023 December 31, 2024 Comment Number of complete doses of eligible COVID-19 vaccine purchased through the project that arrived in the country Value 0.00 2721600.00 2721600.00 Date April 30, 2021 September 30, 2023 December 31, 2024 Comment Number of sites with functioning refrigerators purchased through the project Value 0.00 523.00 540.00 Date April 30, 2021 September 30, 2023 June 30, 2024 Comment Number of health workers trained in vaccine administration within the project Value 0.00 2913.00 4000.00 Date April 30, 2021 September 30, 2023 June 30, 2024 Comment Number of female health workers trained in vaccine administration within the project Value 0.00 1480.00 2200.00 Date April 30, 2021 September 30, 2023 June 30, 2024 Comment Number of vaccination sites that received waste treatment equipment through the project. Value 0.00 2832.00 2720.00 Date April 30, 2021 September 30, 2023 June 30, 2024 Comment Proportion of serious adverse events following immunization (AEFI) reported and investigated based on national guidelines Value 0.00 100.00 100.00 Date April 30, 2021 September 30, 2023 June 30, 2024 Comment Percentage of frontline health care workers with the knowledge to recognize, medically manage, and refer GBV survivors to appropriate services Value 0.00 7.73 24.00 Date April 30, 2021 September 30, 2023 June 30, 2024 Comment Percentage of immunization sites reporting data on time Value 0.00 100.00 80.00 Date April 30, 2021 September 30, 2023 June 30, 2024 Comment Percentage of recorded grievances that are addressed in a timely manner Value 0.00 78.00 75.00 Date April 30, 2021 September 30, 2023 June 30, 2024 Comment Percentage of doses successfully administered out of the total vaccine doses procured by the Project Value 0.00 5.50 70.00 Date December 1, 2021 September 30, 2023 December 31, 2024 Comment